Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of β-amyloid pathology
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
&NA; Obesity and type 2 diabetes mellitus (T2DM) are important risk factors for Alzheimer's disease (AD). Drugs originally developed for T2DM treatment, e.g., analog of glucagon‐like peptide 1 liraglutide, have shown neuroprotective effects in mouse models of AD. We previously examined the neuroprotective properties of palm11‐PrRP31, an anorexigenic and glucose‐lowering analog of prolactin‐releasing peptide, in a mouse model of AD‐like Tau pathology, THY‐Tau22 mice. Here, we demonstrate the neuroprotective effects of palm11‐PrRP31 in double transgenic APP/PS1 mice, a model of AD‐like &bgr;‐amyloid (A&bgr;) pathology. The 7‐8‐month‐old APP/PS1 male mice were subcutaneously injected with liraglutide or palm11‐PrRP31 for 2 months. Both the liraglutide and palm11‐PrRP31 treatments reduced the A&bgr; plaque load in the hippocampus. Palm11‐PrRP31 also significantly reduced hippocampal microgliosis, consistent with our observations of a reduced A&bgr; plaque load, and reduced cortical astrocytosis, similar to the treatment with liraglutide. Palm11‐PrRP31 also tended to increase neurogenesis, as indicated by the number of doublecortin‐positive cells in the hippocampus. After the treatment with both anorexigenic compounds, we observed a significant decrease in Tau phosphorylation at Thr231, one of the first epitopes phosphorylated in AD. This effect was probably caused by elevated activity of protein phosphatase 2A subunit C, the main Tau phosphatase. Both liraglutide and palm11‐PrRP31 reduced the levels of caspase 3, which has multiple roles in the pathogenesis of AD. Palm11‐PrRP31 increased protein levels of the pre‐synaptic marker synaptophysin, suggesting that palm11‐PrRP31 might help preserve synapses. These results indicate that palm11‐PrRP31 has promising potential for the treatment of neurodegenerative diseases. HIGHLIGHTSPalm11‐PrRP31 is an anorexigenic and glucose‐lowering analog of PrRP.Palm11‐PrRP31 treatment was neuroprotective in APP/PS1 mice, a model of amyloidosis.The treatment reduced &bgr;‐amyloid plaque load, microgliosis and astrogliosis.The treatment reduced Tau phosphorylation and tended to increase adult neurogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microglia in Alzheimer’s disease
Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935 · cited 1×
“These activated microglia may then participate in Aβ-induced synapse loss and exacerbate Tau pathology and secrete inflammatory factors that activate astrocytes (reviewed in (Hansen et al., 2018)).”
Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums
Arnold, S. E., Arvanitakis, Z., Macauley-Rambach, S. L., Koenig, A. M., Wang, H.-Y., Ahima, R. S., Craft, S., Gandy, S., Buettner, C., Stoeckel, L. E., et al. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.185 · Cited by 1,597
The GSK3 hypothesis of Alzheimer’s disease
Hooper, C., Killick, R., & Lovestone, S. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05194.x · Cited by 1,191
McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698
Self-citationCaspase-cleavage of tau is an early event in Alzheimer disease tangle pathology
Rissman, R. A., Poon, W. W., Blurton-Jones, M., Oddo, S., Torp, R., Vitek, M. P., LaFerla, F. M., Rohn, T. T., & Cotman, C. W. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420640 · Cited by 543 · cited 1×
“, 2017) and contributes to neurofibrillary tangles formation by cleaving the Tau protein, which then catalyzes pathological assembly of Tau filaments (Rissman et al., 2004).”
Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease
Morris, G. P., Clark, I. A., & Vissel, B. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0135-5 · Cited by 522
Update on Alzheimer’s Disease Therapy and Prevention Strategies
Graham, W. V., Bonito-Oliva, A., & Sakmar, T. P. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-042915-103753 · Cited by 506 · cited 1×
“The pathogenesis of AD is very complex, and therapeutic strategies directly targeting its pathological hallmarks have shown little to no efficacy in clinical trials (Graham et al., 2017; Morris et al., 2014).”
Tau and neuroinflammation: what impact for Alzheimer's disease and tauopathies?
Laurent, C., Buée, L., & Blum, D. (2018) · Biomedical Journal · doi:10.1016/j.bj.2018.01.003 · Cited by 348 · cited 1×
“Hyperphosphorylation lowers binding of Tau to tubulin and promotes Tau selfpolymerization and aggregation of neurofibrillary tangles (Laurent et al., 2018; Mietelska-Porowska et al., 2014).”
Cho, J., & Johnson, G. V. W. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02155.x · Cited by 282
Tau Oligomers: The Toxic Player at Synapses in Alzheimer’s Disease
Guerrero-Muñoz, M. J., Gerson, J., & Castillo-Carranza, D. L. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00464 · Cited by 168
Cited by
Reich, N., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.970925 · Cited by 248
Self-citationBrain insulin resistance: role in neurodegenerative disease and potential for targeting
Hölscher, C. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1738383 · Cited by 180
Self-citationAnti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179583 · Cited by 148
The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
Du, H., Meng, X., Yao, Y., & Xu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1033479 · Cited by 125
Cheng, D., Yang, S., Zhao, X., & Wang, G. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s348055 · Cited by 84
Metadata
- Authors
- Holubová, M., Hrubá, L., Popelová, A., Bencze, M., Pražienková, V., Gengler, S., Kratochvílová, H., Haluzík, M., Železná, B., Kuneš, J., Hölscher, C., & Maletínská, L.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 144
- Pages
- 377-387
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2900189832
- Cited by
- 82
- References
- 10
- FWCI
- 4.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of β-amyloid pathology. https://app.cochat.ai/papers/10.1016/j.neuropharm.2018.11.002
- The paper
- Holubová, M., Hrubá, L., Popelová, A., Bencze, M., Pražienková, V., Gengler, S., Kratochvílová, H., Haluzík, M., Železná, B., Kuneš, J., Hölscher, C., & Maletínská, L. (2019). Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of β-amyloid pathology. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2018.11.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.